Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme acquired 190,000 existing shares on-market on 10 June 2026 to satisfy future vesting obligations.

The purchase was executed at an average price of HK$33.78 per share, representing a total cash outlay of HK$6.42 million, excluding related fees and levies. The newly acquired shares equal approximately 0.0509% of the company’s issued share capital.

Following this transaction, the trustee holds 2.51 million shares under the 2022 RSU Scheme. In line with the trust deed, the trustee will not exercise voting rights attached to any shares it holds.

The company reiterated that, aside from the initial and subsequent grants disclosed on 23 June 2022, 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025, and 20 April 2026, no additional awards have been granted under the 2022 RSU Scheme.